London, UK and Toronto, Canada 7 November, 2022 – Resolution Therapeutics Limited (“Resolution”), a biopharmaceutical company developing macrophage cell therapies to treat advanced liver disease, CCRM, one of the leading companies developing and commercializing regenerative medicine-based technologies and cell and gene therapies, and OmniaBio Inc., CCRM’s subsidiary, today announced a research collaboration to develop and scale up a manufacturing platform for Resolution’s off-the-shelf iPSC-derived macrophage cell therapies. [Read more…]
Tempo Bioscience Expands Patient-Relevant Blood-Brain-Barrier Models for Drug Development
San Francisco, CA, October 19, 2022 – Tempo Bioscience, Inc. (“Tempo”) a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell (iPSC) derived cell products and affiliated cell-based services in the following categories:
- Tempo-iBMEC™ – Human iPSC-derived Brain Microvascular Endothelial Cells
- Tempo-iPeri™ – Human iPSC-derived Pericytes
I Peace partners with the California Institute for Regenerative Medicine [CIRM]
PALO ALTO, Calif., Nov. 1, 2022 — I Peace, Inc. announced that the company has agreed to join the California Institute for Regenerative Medicine’s (CIRM) Industry Resource Partner Program to pave way for the provision of Good Manufacturing Practice (GMP) iPSCs for various research programs funded by CIRM. I Peace has been providing GMP Induced Pluripotent Stem Cells (iPSC) for a variety of cell therapy developers and pharmaceutical companies in the past several years and we believe this wonderful partnership with CIRM reflects the high-quality of our cell products and accompanying services. [Read more…]
Perinatal Stem Cell Society Calls Emergency Session to Garner Industry Support for FDA
FORT LAUDERDALE, Fla., Oct. 26, 2022 — The Perinatal Stem Cell Society has organized a workshop Nov. 3 in Fort Lauderdale, Fla. and streamed to unite the biologics industry and work with the FDA towards a patient-centered goal.
“I called this one-day workshop so the industry can partner with the Food and Drug Administration to find solutions that will enable access to affordable stem cell therapies and biological treatments for patients in the United States,” said CEO and co-founder Kyle Cetrulo. [Read more…]
FUJIFILM Diosynth Biotechnologies & RoosterBio Announce Collaboration to Enable GMP Manufacturing of Cell & Exosome Therapies
College Station, Texas, October 24 2022 — FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, announced today a strategic collaboration with RoosterBio, Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services. Through this collaboration, FUJIFILM Diosynth Biotechnologies will incorporate RoosterBio’s industry-leading process development technology for both MSC and extracellular vesicle (EV) / exosome programs into its manufacturing capabilities and offerings. [Read more…]
- « Previous Page
- 1
- …
- 54
- 55
- 56
- 57
- 58
- …
- 119
- Next Page »